In contrast, a recently published 12‐month RCT from the Steno Diabetes Centre,50 which included PwT2D treated with insulin therapy (≥1 insulin injection/day), showed that rtCGM improved glucose time in range and was associated with greater self‐rated diabetes‐related health, well‐being, satisfaction and health behaviour compared with SMBG. The gene discussed is INS; the disease is diabetes mellitus.